Trial Profile
A Phase 1 Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) as First-Line Treatment.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Nov 2017
Price :
$35
*
At a glance
- Drugs Linifanib (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Apr 2012 Planned End Date changed from 1 Dec 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 23 Jan 2012 Planned end date changed from 1 Mar 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.